article thumbnail

IPC alert advises patients to monito possibility of mefenamic acid’s adverse effects: Meftal makers

Express Pharma

DRESS syndrome, mentioned in the IPC alert, is a very rare event that is previously documented in medical literature, both in India and globally. The post IPC alert advises patients to monito possibility of mefenamic acid’s adverse effects: Meftal makers appeared first on Express Pharma.

article thumbnail

Common Adverse Reactions to EGFR Therapy

Pharmacy Times

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AZ, J&J COVID-19 vaccine trials okay to restart in US

pharmaphorum

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. There are many possible factors that could have caused the event.”.

article thumbnail

Therapeutic-first for cold agglutinin disease haemolytic anaemia

European Pharmaceutical Review

The study found 96 percent of patients who recieved Enjaymo ® and all participants in the placebo group experienced at least one treatment emergent adverse event (TEAE). Serious adverse reactions (SARs) were reported in 13 percent (3/24) of patients who received the mAb. Headache (22.7 percent vs 10.0

article thumbnail

New CAR-T therapies in South Korea to face stringent regulatory oversight: GlobalData

Express Pharma

This will ensure a comprehensive database of adverse events including malignancies, if any in the local population, thereby ensuring patient safety in the country. However, regulatory focus on malignancy data might extend clinical trial timelines and increase costs for pipeline therapies, says GlobalData.

article thumbnail

FDA approves first gene therapy for high-risk early bladder cancer

European Pharmaceutical Review

The failure to achieve a complete response (CR), or the disappearance of all signs of cancer as seen on cystoscopy, biopsied tissue, and urine, is associated with an increased risk of death or a disease-worsening event. Without treatment, the cancer can invade, damage tissues and organs, and spread through the body.

article thumbnail

FDA approves first treatment for geographic atrophy

European Pharmaceutical Review

A milestone for retinal ophthalmology The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade.” It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.